Cognito Therpaetuics announced the closing of its oversubscribed $105 funding round this week, along with Nexcure launching with a $19 million Series A backing.

The financing rounds display investors’ continued effort to back innovative approaches to some of medicine's most difficult access and treatment challenges.

Cognito Therapeutics closes $105 million Series C

Cognito Therapeutics has closed an oversubscribed $105 million Series C round, led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with new investors including Apollo Health Ventures and Benvolio Group also participating.¹

The funding is expected to support a pivotal data readout, regulatory submission, and commercial launch preparation ahead of an anticipated 2027 market entry for Spectris, the company's investigational at-home therapy for Alzheimer's disease.¹

The capital is also expected to help advance the Spectris platform into additional neurodegenerative indications through a network of brain health collaborators, beginning with the WVU Rockefeller Neuroscience Institute.

What is Spectris?

Spectris is a non-invasive device that delivers coordinated visual and auditory stimulation through the brain's natural sensory pathways, with the goal of preserving cognition, daily function, and brain structure in Alzheimer's patients.¹ The company's HOPE pivotal study is fully enrolled, with top-line data expected later this year.

Christian Howell, CEO of Cognito Therapeutics, described Spectris as potentially the world's first physician-prescribed, at-home neuroprotective therapy for Alzheimer's patients. Gerald Chan, founder of Morningside Ventures and chairman of the board at Cognito, said the therapy has the potential to redefine treatment of a broad category of neurodegenerative diseases by moving care into the home and scaling impact globally.

“With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease,” said Howell. “Spectris has the potential to become the world’s first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most.”

NexCure launches with $19 million to bring CAR-T therapy to community settings

NexCure launched this week with a $19 million Series A round led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures, to address a stark access gap in CAR-T therapy delivery.

According to the company, it launched to address the lack of CAR-T treatments, as only around 200 of the approximately 6,100 hospitals in the U.S currently administer CAR-T treatments.²

Founded by Raven, RA Capital's healthcare incubator, NexCure is expected to combine purpose-built outpatient clinics with a proprietary technology platform designed to standardize protocols, automate care coordination, and reduce operational variability.²

The goal of Nexcure is to make clinically intensive therapies deliverable beyond the small number of academic medical centers that currently offer them, removing geographic, financial, and logistical barriers for patients.²

The financing round is expected to be used to build out NexCure's operating system for advanced therapy delivery, integrating clinical decision support, remote monitoring, and operational intelligence.²

Sophie Papa, founder and chief medical officer at NexCure, said the company is focused on overcoming the operational barriers that prevent care providers from offering these treatments more widely.

Paul Rothman, venture partner at Raven and board chair of NexCure, noted that as CAR-T expands beyond oncology into autoimmune diseases, the need for a scalable, community-based delivery model will only grow.

"Today, only a fraction of patients who are eligible for CAR-T therapy actually receive it, largely due to where and how care is delivered," said Rothman. "As CAR-T matures and moves beyond oncology into autoimmune and other diseases, NexCure will work in partnership with the health ecosystem to thoughtfully expand access so more patients can receive advanced therapies in settings that are safe, effective and closer to home."

Sources

1. Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease Cognito Therapeutics March 5, 2026 https://www.businesswire.com/news/home/20260305121811/en/Cognito-Therapeutics-Announces-Oversubscribed-%24105-Million-Series-C-Financing-to-Advance-Spectris-in-Alzheimers-Disease
2. NexCure, Inc. Launches with $19 Million Series A Financing to enable CAR-T and other advanced treatment delivery in community outpatient settings Nexcure Inc. March 5, 2026 https://www.prnewswire.com/news-releases/nexcure-inc-launches-with-19-million-series-a-financing-to-enable-car-t-and-other-advanced-treatment-delivery-in-community-outpatient-settings-302704602.html